Ken says: "If you were, for example, a small company called Respert Drugs Etalia, wouldn't you want a drug you could sell as part of ALL treatment vs. solid tumor cells -- instead of just treatments that use Keytruda (for example)?
Answer is probably: Hell yes."
The answer is most definitely hell yes.
Here at Respert Drugs Etalia we have two goals. Our first goal, and the stated mission of the company, is to take patient care from band-aids to cures. Specifically in cancer. And the second goal is to prove once and for all that liquor before beer means you're in the clear. That beer before liquor means you'll never be sicker. That we can all stop pretending that pinot noir is delicious, that cauliflower can be a substitute for anything that doesn't already taste like antique farts, or that leaving the tails on shrimp in any dish that isn't peel-n-eat is ok.
We aren't your typical pharma company. We actually care.
Now I will tamper everyone's expectations and tell you right now that we're leveraged to our eyeballs in Cabernet futures and next-gen wagyu farms. We simply can't afford a company like Cytodyn right now.
But take a company like Boehringer Ingelheim, for example. Here are their main therapeutic areas. I've bolded a couple that stand out for no particular reason:
Cardio-Renal-Metabolic (CRM): Focuses on interconnected diseases like type 2 diabetes, heart failure, stroke , and chronic kidney disease (CKD).
Respiratory Diseases: A 100-year heritage including Chronic Obstructive Pulmonary Disease (COPD), asthma, Idiopathic Pulmonary Fibrosis (IPF) , and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD).
Oncology & Cancer Immunology : Develops targeted therapies for non-small cell lung cancer (NSCLC), gastrointestinal cancers, and specialized cancer immunotherapies.
Immunology: Focuses on chronic, inflammatory diseases such as Generalized Pustular Psoriasis (GPP).
Central Nervous System (CNS) / Mental Health: Targets schizophrenia and Alzheimer's disease with a focus on precision psychiatry.
Retinal Health: Tackles eye diseases like age-related macular degeneration (AMD) and diabetic retinopathy.
By my estimation they don't have an ICI on the market but seem to be trying to get in the mix .
Why wouldn't BI want to take control of a drug like Leronlimab? They already have an oncology program with desire to not only grow it, but to get a piece of the ICI market as well.
They're private and can do things a publicly traded company might not as easily do, like overpay for a company. And ultimately there are likely many Boehringer-like companies eager to make a bigger splash in the oncology market. I wouldn't be surprised to end up finding out that one or two of these kinds of companies get in the bidding process before it all shakes out.
Answer is probably: Hell yes."
The answer is most definitely hell yes.
Here at Respert Drugs Etalia we have two goals. Our first goal, and the stated mission of the company, is to take patient care from band-aids to cures. Specifically in cancer. And the second goal is to prove once and for all that liquor before beer means you're in the clear. That beer before liquor means you'll never be sicker. That we can all stop pretending that pinot noir is delicious, that cauliflower can be a substitute for anything that doesn't already taste like antique farts, or that leaving the tails on shrimp in any dish that isn't peel-n-eat is ok.
We aren't your typical pharma company. We actually care.
Now I will tamper everyone's expectations and tell you right now that we're leveraged to our eyeballs in Cabernet futures and next-gen wagyu farms. We simply can't afford a company like Cytodyn right now.
But take a company like Boehringer Ingelheim, for example. Here are their main therapeutic areas. I've bolded a couple that stand out for no particular reason:
Cardio-Renal-Metabolic (CRM): Focuses on interconnected diseases like type 2 diabetes, heart failure, stroke , and chronic kidney disease (CKD).
Respiratory Diseases: A 100-year heritage including Chronic Obstructive Pulmonary Disease (COPD), asthma, Idiopathic Pulmonary Fibrosis (IPF) , and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD).
Oncology & Cancer Immunology : Develops targeted therapies for non-small cell lung cancer (NSCLC), gastrointestinal cancers, and specialized cancer immunotherapies.
Immunology: Focuses on chronic, inflammatory diseases such as Generalized Pustular Psoriasis (GPP).
Central Nervous System (CNS) / Mental Health: Targets schizophrenia and Alzheimer's disease with a focus on precision psychiatry.
Retinal Health: Tackles eye diseases like age-related macular degeneration (AMD) and diabetic retinopathy.
By my estimation they don't have an ICI on the market but seem to be trying to get in the mix .
Why wouldn't BI want to take control of a drug like Leronlimab? They already have an oncology program with desire to not only grow it, but to get a piece of the ICI market as well.
They're private and can do things a publicly traded company might not as easily do, like overpay for a company. And ultimately there are likely many Boehringer-like companies eager to make a bigger splash in the oncology market. I wouldn't be surprised to end up finding out that one or two of these kinds of companies get in the bidding process before it all shakes out.
12
